Are CV studies worth it for diabetes meds? After Merck and Sanofi’s recent successes, some say no

Carly Helfand

industry watchers are wondering whether those large, expensive trials–which aren't long enough to establish long-term outcomes–were it.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS